EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB ‐9778

Lina El Badaoui iD, Stipo Jurcevic iD, Yotis A Senis iD, Alastair J Barr iD

Pharmacology Research & Perspectives · 2026-08 · 14 (4)

DOI: 10.1002/prp2.70301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 31.07.2026. Verfasst von Lina El Badaoui und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, University of Westminster, London, UK. Hauptthemen laut MEDLINE: Receptor-Like Protein Tyrosine Phosphatases, Class 3, Fibrinolytic Agents, Thrombosis. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD148 is the primary receptor‐type protein tyrosine phosphatase (PTP) regulating platelet activation, and its inhibition has been proposed as a novel anti‐thrombotic strategy with potentially lower bleeding risk than current therapies. However, selective and potent inhibitors of CD148 are currently lacking. AKB‐9778 (razuprotafib), a potent inhibitor of the closely related vascular endothelial‐PTP (VE‐PTP), has also been reported to inhibit CD148. This study investigated the effect of AKB‐9778 on in vitro whole‐blood thrombogenicity, examined the molecular basis of its interaction with the CD148 catalytic domain using molecular docking, and assessed inhibitor selectivity with an in vitro phosphatase assay. In a total‐thrombus formation analysis system (T‐TAS), AKB‐9778 partially inhibited thrombus formation, reducing AUC 10 by 28%, without significantly affecting occlusion start time or occlusion time. The inhibitor did not alter collagen‐stimulated CD62P platelet surface expression or PAC‐1 binding to the activated integrin αIIbβ3. Molecular docking using CB‐Dock predicted a binding configuration in which the phenylsulfamic acid group of AKB‐9778 is orientated towards the catalytic cysteine, with additional conformations reflecting ligand flexibility. Site‐directed mutagenesis of Tyr1071, Gln1283, His1206, and Asn1073 to alanine reduced the inhibitory effect in phosphatase assays, supporting interaction with these residues. Notably, the IC 50 of AKB‐9778 against CD148 was approximately 300‐fold higher than previously reported values, consistent with the wide variability across studies. Despite this reduced potency, these findings support the concept of CD148 inhibition as a potential anti‐thrombotic strategy and suggest that AKB‐9778 may serve as a useful prototype for developing more selective and efficacious CD148 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor-Like Protein Tyrosine Phosphatases, Class 3Fibrinolytic AgentsThrombosisHumansMolecular Docking SimulationBlood PlateletsAnimalsCatalytic DomainPlatelet Activation

Stichwörter der Autor:innen

AKB‐9778CD148PTPRJT‐TASVE‐PTPmolecular dockingplateletsrazuprotafibreceptor‐type protein tyrosine phosphatasethrombosis

Substanzen

Receptor-Like Protein Tyrosine Phosphatases, Class 3Fibrinolytic Agents

Autor:innen und Institutionen

  • School of Life Sciences, University of Westminster, London, UK.
  • Centre for Cardiovascular and Nutrition Research, INSERM 1263, INRAE 1260, Faculty of Medicine, Aix-Marseille University, Marseille, France.

ORCID-Profile: Lina El Badaoui, Stipo Jurcevic, Yotis A Senis, Alastair J Barr

Zitieren

APA

El Badaoui, L., Jurcevic, S., Senis, Y. A., & Barr, A. J. (2026). Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB ‐9778. Pharmacology Research & Perspectives, 14(4). https://doi.org/10.1002/prp2.70301

Vancouver

El Badaoui L, Jurcevic S, Senis YA, Barr AJ. Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB ‐9778. Pharmacology Research & Perspectives. 2026;14(4). doi:10.1002/prp2.70301

BibTeX
@article{ElBadaoui2026,
  author = {El Badaoui, Lina and Jurcevic, Stipo and Senis, Yotis A and Barr, Alastair J},
  title = {Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB ‐9778},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1002/prp2.70301}
}
Kostenlos starten →